Erschienen in:
01.08.2014 | Bone and Soft Tissue Sarcomas
Radiation Therapy for Extremity Soft Tissue Sarcoma: In the Absence of a Clear Survival Benefit, Why Do We Give It?
verfasst von:
Elizabeth H. Baldini, MD, MPH, Chandrajit Raut, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2014
Einloggen, um Zugang zu erhalten
Excerpt
Due in large part to several sentinel contributions from the National Cancer Institute (NCI), the local management of extremity soft tissue sarcoma (ESTS) today typically results in excellent local control and very good limb function. In 1982, Rosenberg et al.
1 showed equivalent 5-year survival rates for limb-sparing surgery (LSS) plus radiation therapy (RT) compared with amputation and an acceptable 15 % local recurrence (LR) rate for LSS plus RT. Following publication of this landmark trial, amputation rates appropriately plummeted. In 1998, Yang et al.
2 reported results from a second NCI randomized trial that compared LSS plus RT with LSS alone and showed a clear significant local control benefit for RT for both high- and low-grade ESTS. A randomized trial from Memorial Sloan-Kettering Cancer Center (MSKCC) in 1996 affirmed the local control advantage for RT (in the form of brachytherapy) in addition to LSS.
3 Several nonrandomized series have reported LR rates <15 % for LSS alone without RT, but others have shown unacceptably high rates of LR with this approach.
4‐
8 Given the conflicting results for surgery alone from nonrandomized reports, and the clear local control advantage with RT demonstrated by randomized trials, the standard of care for most high-grade ESTS is LSS plus RT. …
